Core Viewpoint - The article highlights the diversification and expansion of the fund manager talent pool in the investment industry, with a notable increase in the number of new fund managers since 2026, reflecting the growth and innovation within the fund management sector [1][7]. Group 1: New Fund Managers - As of March 5, 2026, over 100 new fund managers have been appointed, indicating a robust influx of talent into the industry [7]. - Among the new appointees, many possess high educational qualifications, with 99 out of 102 having master's degrees or higher, including 9 PhDs [7]. - The trend shows a shift towards younger fund managers, with 50.9% of the current fund manager cohort being born in the 1980s and 1990s [10]. Group 2: Individual Case Study - Jia Zhi - Jia Zhi has been appointed as a new fund manager at Green Fund, bringing 23 years of experience in the securities industry, including roles at various securities firms and investment advisory companies [2][3]. - His investment style focuses on industry rotation, selective stock picking, and deep research, aiming to achieve returns that exceed performance benchmarks [4][6]. - Jia Zhi has actively engaged with investors through platforms like Ant Wealth, where he has a following of 796,000 and has reported a one-year return of 32.38% on his investments [4]. Group 3: Industry Trends - The fund management industry is experiencing a significant increase in the number of fund managers, with the total number reaching 4,146 as of March 5, 2026 [7]. - The transition from sell-side to buy-side roles is becoming more common, with many new fund managers having previously worked as researchers, often within a shorter timeframe [8]. - Despite the growth in numbers, there are concerns regarding the stability and experience of the fund manager workforce, with an average tenure of only 5.15 years [10].

Core Insights - The public fund market will see the launch of 29 new funds in the first week of February 2026, with equity products remaining the dominant category [1] Fund Distribution - Among the 29 new funds, there are 11 equity funds, 7 mixed funds, 6 FOFs (Fund of Funds), and 5 bond funds, with an average subscription period of 12 days [3] - Active equity products include 8 funds with an average subscription period of approximately 13 days, including 2 pharmaceutical-themed products: Shangyin Medical Selection and Guangfa Medical Innovation Selection, the latter having a fundraising cap of 8 billion units and a subscription period of 3 days [4] - Passive index products feature themes such as biotechnology, non-ferrous metals, and batteries, with an average subscription period of 10 days. Three products have a fundraising cap of 8 billion units: E Fund CSI Battery Theme ETF, Bosera CSI Industrial Non-Ferrous Metals Theme ETF, and E Fund CSI All-Share Dividend Quality ETF [4] - The 6 FOFs have an average subscription period of about 11 days, all with a 3-month holding period, and three have a fundraising cap of 8 billion units: Guangfa Yuefeng Multi-Asset Stable Three-Month Holding, Guotou Ruijin Multi-Asset Stable Three-Month Holding, and Tianhong Yingxiang Multi-Asset Leading Three-Month Holding [4] - The 5 bond funds have an average subscription period of approximately 18 days, with Luobomai Tianhang and Nongyin Ruiheng setting a fundraising cap of 6 billion units [4]

在相关指数中，恒生生物科技指数（HSBIO.HI）以"高纯度"和稀缺性凸显配置价值。指数精选30家纳 入港股通、市值领先的生物科技公司，覆盖18A规则上市的龙头企业，剔除传统制药，集中布局小核 酸、双抗、细胞治疗等A股相对稀缺的前沿技术平台，AH股重合度小于20%，具有差异化配置价值。指 数成分股100%属于医疗保健业，前十大权重股占比约70%，网罗药明生物、百济神州、信达生物等生 物技术和药品龙头。业绩表现高弹性，截至1月29日，恒生生物科技指数近一年涨幅达82.2%，显著跑 赢医疗医药板块同类指数。 为便利投资者高效布局港股生物科技核心资产，广发基金于2月2日至6日推出广发恒生生物科技ETF （场内简称：恒生生物科技ETF广发，代码：159169）。该ETF支持T+0交易，无QDII额度限制，低门 槛更便捷，整体费率在同类跨境ETF中处于低档位。随着生物科技景气度回升、港股流动性优势显现， 恒生生物科技ETF有望助力投资者高效把握中国生科企业在全球化进程中的结构性机遇。 近年来，生物科技产业加速发展，已成为全球科技革命与产业升级的重要方向。创新药作为行业核心引 擎，与"健康中国"战略高度契合，也是培育新质 ...